Description
Kisqali (Ribociclib) 200mg Online
Kisqali (Ribociclib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. And It is used to treat breast cancer, leukemia, melanoma, lung cancer, and renal cancer. They are also used in the treatment of rheumatoid arthritis and to prevent organ transplant rejection. They work by stopping cancer cell growth and preventing the spread of the cells.
Kisqali (Ribociclib) is used in combination with another medication to treat a certain type of hormone receptor-positive (depends on hormones such as estrogen to grow) advanced breast cancer or that has spread to other parts of the body in women who have not experienced menopause (change of life; end of monthly menstrual periods) and in those who are close to or who have already experienced menopause. Ribociclib is also used in combination with fulvestrant (Faslodex) to treat a certain type of hormone-receptor-positive advanced breast cancer or that has spread to other parts of the body as an initial treatment or in people who have not been treated successfully with other treatments in women who have already experienced menopause. Kisqaliis in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Kisqali is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-cyclins and play a crucial role in signalling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).
